Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Sees Large Increase in Short Interest

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 8,509,923 shares, an increase of 234.4% from the April 15th total of 2,544,706 shares. Based on an average daily volume of 79,730,843 shares, the days-to-cover ratio is presently 0.1 days. Approximately 25.4% of the shares of the stock are short sold.

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently raised its stake in Theriva Biologics stock. Geode Capital Management LLC grew its stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 212,087 shares of the company’s stock after acquiring an additional 183,878 shares during the period. Geode Capital Management LLC owned about 0.63% of Theriva Biologics worth $45,000 as of its most recent filing with the SEC. 6.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $1.00.

Theriva Biologics Trading Down 2.7%

Shares of Theriva Biologics stock traded down $0.01 on Thursday, reaching $0.32. The company had a trading volume of 2,076,673 shares, compared to its average volume of 45,291,652. The firm’s 50 day moving average price is $0.26 and its two-hundred day moving average price is $0.24. The firm has a market cap of $10.83 million, a PE ratio of -0.01 and a beta of 1.17. Theriva Biologics has a 52-week low of $0.16 and a 52-week high of $0.86. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.63 and a current ratio of 1.63.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.05) earnings per share (EPS) for the quarter.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.